Co-DiagnosticsHAM:C970 63 FCF Yield % is -257.05 as of Jun. 27, 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Co-Diagnostics ranks worse than 98.01% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Co-Diagnostics's FCF Yield % or its related term are showing as below:
HAM:C970'
s FCF Yield % Range Over the Past 10 Years
Min: -1005.19 Med: -16.24 Max: 25.76
Current: -257.05
During the past 11 years, the highest FCF Yield % of Co-Diagnostics was 25.76%. The lowest was -1005.19%. And the median was -16.24%.
HAM:C970's FCF Yield % is ranked worse than 98.01% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.38
vs HAM:C970: -257.05
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Co-Diagnostics FCF Yield % Related Terms
Co-Diagnostics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs CTSO, NMTC, RDGL: FCF Yield % Comparison
For the Medical Devices subindustry, Co-Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (HAM:C970) has a FCF Yield % of -257.05 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Co-Diagnostics and its competitors. According to the industry distribution chart, Co-Diagnostics ranks #838 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is Co-Diagnostics' FCF Yield % too high?
Co-Diagnostics' current FCF Yield % is -257.05. Based on the distribution chart, Co-Diagnostics ranks #838 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' FCF Yield % compare to CTSO and NMTC?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #838 out of 855 companies for FCF Yield %. This places Co-Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current FCF Yield % is -257.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current FCF Yield % of -257.05. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current FCF Yield % is -257.05. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current FCF Yield % is -257.05 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.
Key valuation signals for HAM:C970:
FCF Yield %: -257.05
GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score
Get the complete analysis for HAM:C970
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
